Treatment Effect Waning in Immuno-oncology Health Technology Assessments: A Review of Assumptions and Supporting Evidence with Proposals to Guide Modelling
PharmacoEconomics · 2024-11 · 42 (11) · 1181-1196
DOI: 10.1007/s40273-024-01423-6 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift PharmacoEconomics, online erschienen am 23.08.2024. Verfasst von Kurt Taylor und 9 weiteren Autor:innen. Beteiligte Einrichtung: Delta Hat Limited, Nottingham, UK. ktaylor@deltahat.com. Hauptthemen laut MEDLINE: Technology Assessment, Biomedical, Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Bristol-Myers Squibb.
Abstract (Originalsprache)
Treatment effect waning (TEW) refers to the attenuation of treatment effects over time. Assumptions of a sustained immuno-oncologic treatment effect have been a source of contention in health technology assessment (HTA). We review how TEW has been addressed in HTA and in the wider scientific literature. We analysed company submissions to English language HTA agencies and summarised methods and assumptions used. We subsequently reviewed TEW-related work in the ISPOR Scientific Presentations Database and conducted a targeted literature review (TLR) for evidence of the maintenance of immuno-oncology (IO) treatment effects post-treatment discontinuation. We found no standardised approach adopted by companies in submissions to HTA agencies, with immediate TEW most used in scenario analyses. Independently fitted survival models do however suggest TEW may often be implicitly modelled. Materials in the ISPOR scientific database suggest gradual TEW is more plausible than immediate TEW. The TLR uncovered evidence of durable survival in patients treated with IOs but no evidence that directly addresses the presence or absence of TEW. Our HTA review shows the need for a consistent and appropriate implementation of TEW in oncology appraisals. However, the TLR highlights the absence of direct evidence on TEW in literature, as TEW is defined in terms of relative treatment effects-not absolute survival. We propose a sequence of steps for analysts to use when assessing whether a TEW scenario is necessary and appropriate to present in appraisals of IOs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Delta Hat Limited, Nottingham, UK. ktaylor@deltahat.com.
- Delta Hat Limited, Nottingham, UK.
- Sheffield Centre for Health and Related Research, University of Sheffield, Sheffield, UK.
- Department of Statistical Science, University College London, London, UK.
- Bristol Myers Squibb, Uxbridge, London, UK.
- Bristol Myers Squibb, Lawrenceville, NJ, USA.
ORCID-Profile: Kurt Taylor
Förderung
- Bristol-Myers Squibb
Zitieren
APA
Taylor, K., Latimer, N. R., Douglas, T., Hatswell, A. J., Ho, S., Okorogheye, G., Borril, J., Chen, C., Kim, I., & Bertwistle, D. (2024). Treatment Effect Waning in Immuno-oncology Health Technology Assessments: A Review of Assumptions and Supporting Evidence with Proposals to Guide Modelling. PharmacoEconomics, 42(11), 1181-1196. https://doi.org/10.1007/s40273-024-01423-6
Vancouver
Taylor K, Latimer NR, Douglas T, Hatswell AJ, Ho S, Okorogheye G, et al. Treatment Effect Waning in Immuno-oncology Health Technology Assessments: A Review of Assumptions and Supporting Evidence with Proposals to Guide Modelling. PharmacoEconomics. 2024;42(11):1181-1196. doi:10.1007/s40273-024-01423-6
BibTeX
@article{Taylor2024,
author = {Taylor, Kurt and Latimer, Nicholas R and Douglas, Thomas and Hatswell, Anthony J and Ho, Sophia and Okorogheye, Gabriel and Borril, John and Chen, Clara and Kim, Inkyu and Bertwistle, David},
title = {Treatment Effect Waning in Immuno-oncology Health Technology Assessments: A Review of Assumptions and Supporting Evidence with Proposals to Guide Modelling},
journal = {PharmacoEconomics},
year = {2024},
volume = {42},
number = {11},
pages = {1181--1196},
doi = {10.1007/s40273-024-01423-6}
}
EUVIMED